Muenster

• REDEFINE 3: A research study to see the effects of CagriSema in people living with diseases in the heart and blood vessels Ended recruitment
  2023-506924-94-00 5 2023-02-28 Cardiovascular disease
• A Study of Tirzepatide (LY3298176) on the Reduction of Morbidity and Mortality in Adults With Obesity (SURMOUNT- MMO) Ended recruitment
  2022-501744-15-00 5 2023-01-23 Obesity, Overweight
• Clinical Study of Fianlimab in Combination With Cemiplimab versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated U … Ended recruitment
  2023-505772-30-00 5 2022-11-09 Melanoma
• Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor Long-term Safety and Efficacy in Subjects Without F508del Ended recruitment
  2024-515637-14-00 5 2022-11-08 Cystic Fibrosis
• A research study to see how well CagriSema helps people with excess body weight lose weight Ended recruitment
  2023-506929-11-00 5 2022-10-17 Overweight and obesity
• A clinical study to determine the dose and assess safety and efficacy of radioimmuntherapy in patients with glioblastoma, where Lutetium 177 … Ended recruitment
  2024-513638-39-00 1 2022-10-17 Surgically treated high grade glioma after concomitant radiochemothera
• A randomized, placebo-controlled, double-blind, multi-center trial to assess efficacy and safety of octreotide subcutaneous depot (CAM2029) … Ended recruitment
  2023-505313-24-00 10 2022-09-30 Polycystic liver disease
• A Phase 3 Open-Label Study of PTC923 (Sepiapterin) in Phenylketonuria Ended recruitment
  2023-509229-31-00 5 2022-09-28 Metabolic Disorders - Phenylketonuria
• A phase II, open-label, single arm study to evaluate the efficacy of Luspatercept in Erythropoiesis-stimulating agent naive lower-risk MDS p … Ended recruitment
  2024-516438-36-00 4 2022-09-13 Patients with very low, low or intermediate risk myelodysplastic syndr
• A study to learn if Rozanolixizumab works and is safe over a long period in adults with relapsing myelin oligodendrocyte glycoprotein antibo … Ended recruitment
  2023-509237-39-00 5 2022-08-02 Myelin oligodendrocyte glycoprotein antibody-associated disease (MOG-A
• Study of efficacy, safety and tolerability of ianalumab versus placebo, in combination with SoC therapy, in participants with active lupus n … Ended recruitment
  2023-508559-37-00 5 2022-07-14 Lupus nephritis
• A trial to learn how well Dato-DXd works and how safe it is compared to standard chemotherapy in adults with triple-negative breast cancer ( … Ended recruitment
  2023-509260-25-00 5 2022-07-12 Locally Recurrent Inoperable or Metastatic Triple-negative Breast Canc
• A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients with Multiple Sclerosis Ended recruitment
  2023-505974-14-00 5 2022-06-23 Multiple Sclerosis (MS)
• A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cho … Ended recruitment
  2023-505764-11-00 4 2022-06-10 Pruritus associated with Primary Sclerosing Cholangitis (PSC)
• IMA401-101 – Treatment of patients with solid tumors with IMA401 TCER®, a bispecific T-cell receptor (Phase I trial); alone or in combinatio … Ended recruitment
  2023-506854-19-00 1 2022-05-19 Solid Tumors
• A Study to Evaluate Long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related … Ended recruitment
  2023-507131-38-00 5 2022-05-16 Neovascular Age-Related Macular Degeneration (nAMD)
• Phase 1/2 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Ca … Ended recruitment
  2023-506265-65-00 1 2022-04-07 Localized Bladder Cancer
• A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adu … Ended recruitment
  2024-514619-88-00 5 2022-03-18 Relapsing Multiple Sclerosis
• A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adu … Ended recruitment
  2024-514618-11-00 5 2022-03-01 Relapsing Multiple Sclerosis
• A study of tucatinib versus placebo in combination with pertuzumab and trastuzumab for subjects with advanced or metastatic HER2+ breast can … Ended recruitment
  2023-503826-37-00 5 2022-02-11 Unresectable locally-advanced or metastatic HER2+ breast cancer
• A Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background N … Ended recruitment
  2023-505696-74-00 5 2022-02-10 systemic lupus erythematosus
• A study to learn how well finerenone works; how safe it is; how it moves into, through, and out of the body; and the effects it has on the b … Ended recruitment
  2023-504884-17-00 5 2022-02-04 Proteinuria
• Study to Evaluate the Safety, Tolerability, and Efficacy of 2000 mg/kg of Trappsol® Cyclo™ and Standard of Care Compared to Placebo and Stan … Ended recruitment
  2024-518266-27-00 5 2022-02-02 Niemann Pick Disease Type C1
• DESTINY-Breast11 will compare trastuzumab deruxtecan (T-DXd) alone or in sequence with other medications, known as THP, with standard of car … Ended recruitment
  2023-505210-18-00 5 2021-12-17 Early stage HER2-positive breast cancer (T stage >= T3, lymph node pos

Showing 361–384 of 608 trials